Clinical Trial

Goal-Directed Therapy to Reduce Kidney and Cardiovascular Risk in Diabetic Kidney Disease (GOLD-STANDARD)

Study acronym: GOLD-STANDARD
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
GOLD-STANDARD is a pragmatic, open-label pilot randomized controlled trial evaluating the feasibility and safety of early goal-directed Cardio-Kidney-Metabolic (CKM) care compared with usual care in patients with diabetic kidney disease. Participants will be randomized 1:1 and managed by nephrologists. The intervention includes structured kidney and cardiovascular risk assessment, early shared decision-making regarding guideline-directed medical therapies, and close monitoring for adverse effects. The usual care group will receive standard clinical management at the discretion of the treating clinician. The study will be conducted in Ontario using existing health care infrastructure.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-19.
Trial Details
NCT Number NCT07434791
Lead Sponsor Sunnybrook Health Sciences Centre
Collaborators: The Kidney Foundation of Canada
Conditions Diabetic Kidney Disease (DKD)
Enrollment 100 participants
Start Date 2026-06
Primary Completion 2028-09 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-05-07